Publications by authors named "M M Muijen"
Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors (i) and interleukin (IL)-12/23i) has been described in a previous scoping review. The literature on the DR of the newest generation of biologics (IL-17/23i) was scarce. The current review provides a literature update on the previous scoping review on the DR of all biologics, including the newest generation, with a focus on the uptake and implementation of DR in practice.
View Article and Find Full Text PDFArticle Synopsis
- Itch is a major symptom of atopic dermatitis (AD) in children, affecting their quality of life, prompting a systematic review and meta-analysis of systemic treatments for itch relief in pediatric patients with AD.
- The study analyzed data from 30 studies, highlighting that treatments like dupilumab, cyclosporin A, abrocitinib, and upadacitinib significantly reduced itch severity, with dupilumab showing the most evidence.
- The findings suggest that these treatments can improve the quality of life for children with AD, emphasizing the need to consider patient-centered goals in treatment decisions as more therapies become available.
Article Synopsis
- A study was conducted to compare the effectiveness of different biologic therapies for psoriasis, including IL17-inhibitors and TNF-α-inhibitors, using real-world data.
- Researchers analyzed data from 1,080 treatment episodes involving 700 psoriasis patients to assess outcomes like the mean Psoriasis Area and Severity Index (PASI) and how many patients achieved PASI90 or PASI75.
- Results showed that patients on adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab had better outcomes than those on etanercept, with ixekizumab and guselkumab leading to even higher rates of achieving PASI90 compared to the other biologics